Tekla Life Sciences Inves... (HQL)
Tekla Life Sciences Investors Statistics
Share Statistics
Tekla Life Sciences Investors has - shares outstanding. The number of shares has increased by 0% in one year.
Shares Outstanding | - |
Shares Change (YoY) | 0% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 33.54% |
Shares Floating | 27.15M |
Failed to Deliver (FTD) Shares | 1.57K |
FTD / Avg. Volume | 1.19% |
Short Selling Information
The latest short interest is 74.12K, so 0.27% of the outstanding shares have been sold short.
Short Interest | 74.12K |
Short % of Shares Out | 0.27% |
Short % of Float | 0.27% |
Short Ratio (days to cover) | 0.41 |
Valuation Ratios
The PE ratio is 4.96 and the forward PE ratio is null. Tekla Life Sciences Investors's PEG ratio is -0.05.
PE Ratio | 4.96 |
Forward PE | n/a |
PS Ratio | 4.88 |
Forward PS | null |
PB Ratio | 0.92 |
P/FCF Ratio | 0 |
PEG Ratio | -0.05 |
Enterprise Valuation
Tekla Life Sciences Investors has an Enterprise Value (EV) of 423.12M.
EV / Sales | 4.88 |
EV / EBITDA | 0 |
EV / EBIT | 0 |
EV / FCF | 0 |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
Current Ratio | 0 |
Quick Ratio | 0 |
Debt / Equity | 0 |
Debt / EBITDA | - |
Debt / FCF | - |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 18.56% and Return on Invested Capital is 0%.
Return on Equity | 18.56% |
Return on Assets | 18.52% |
Return on Invested Capital | 0% |
Revenue Per Employee | $- |
Profits Per Employee | $- |
Employee Count | undefined |
Asset Turnover | 0.19 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -13.89% in the last 52 weeks. The beta is 0.77, so Tekla Life Sciences Investors's price volatility has been higher than the market average.
Beta | 0.77 |
52-Week Price Change | -13.89% |
50-Day Moving Average | 13.42 |
200-Day Moving Average | 14.32 |
Relative Strength Index (RSI) | 17.41 |
Average Volume (20 Days) | 132.23K |
Income Statement
In the last 12 months, Tekla Life Sciences Investors had revenue of 86.69M and earned 85.3M in profits. Earnings per share was 0.
Revenue | 86.69M |
Gross Profit | 86.69M |
Operating Income | 0 |
Net Income | 85.3M |
EBITDA | 0 |
EBIT | n/a |
Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 1 in cash and 0 in debt, giving a net cash position of 1.
Cash & Cash Equivalents | 1 |
Total Debt | 0 |
Net Cash | 1 |
Retained Earnings | 44.13M |
Total Assets | 460.58M |
Working Capital | 281.61K |
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0.
Operating Cash Flow | 0 |
Capital Expenditures | 0 |
Free Cash Flow | 0 |
FCF Per Share | 0 |
Margins
Gross margin is 100%, with operating and profit margins of 0% and 98.4%.
Gross Margin | 100% |
Operating Margin | n/a |
Pretax Margin | 98.4% |
Profit Margin | 98.4% |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
HQL pays an annual dividend of $2.33, which amounts to a dividend yield of 14.01%.
Dividend Per Share | $2.33 |
Dividend Yield | 14.01% |
Dividend Growth (YoY) | 20.51% |
Payout Ratio | 76.64% |
Earnings Yield | 20.16% |
FCF Yield | 0% |
Analyst Forecast
Currently there are no analyst rating for HQL.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | 228.16 |
Piotroski F-Score | 3 |